I-Gamma-linolenic acid iyinxalenye ye-acid acid ecinga ukuba inikezele ngeenzuzo zezempilo. Kufunyanwe ukulwa nokuvuvukala, i-gamma-linolenic acid ichithwa kwizinto ezifana neoli ye-primrose yamafutha , i- borage imbewu yeoli , kunye neoli ye- currant xa isetyenzisiweyo.
Emzimbeni, i-gamma-linolenic acid isetyenziselwa ukuvelisa i-prostaglandins (izinto ezifana ne-hormone ezinceda ukulawula umzimba wokhuseleko lomzimba ).
Ikwahlula njenge-omega-6 fatty acid.
Ukusetyenziswa
Ngenye iyeza, i-gamma-linolenic acid isetyenziswe kwiimeko ezahlukeneyo zempilo:
- utywala
- eczema
- unesifo esingapheliyo
- ukuxinezeleka
- cholesterol ephezulu
- yokuyeka
- syndrome
- psoriasis
- irheumatoid arthritis
Ukongezelela, i-gamma-linolenic acid ixelwe ukukhusela umdlavuza kunye nesifo senhliziyo .
Izinzuzo zezeMpilo
Okwangoku, ininzi yophando kwimiphumo yempilo yokuthatha i-gamma linolenic acid ibandakanye ukusetyenziswa kweoli ye-primrose yeoli kunye / okanye ioli ye-borage. Ekubeni ioli ye-primrose yamafutha kunye neoli ye-borage nganye iqulethe ubuncinci bezinye izinto eziyaziwayo ukuba zichaphazele impilo (njenge-vitamin E), kubalulekile ukuqaphela ukuba i-gamma-linolenic acid ayinakuchaphazeleka ngokupheleleyo kwimpilo yeoli.
Nanku ukukhangela kwezinye iziphumo zophando eziphambili:
1) I-eczema
Ioli ye-primrose yohlwaya inokukunceda ukukhupha, ukuqhayisa, ukubomvu, nokuvuvukala okunxulumene ne- eczema , ngokwemeta-analysis epapashwe kwi- Current Pharmaceutical Biotechnology ngo-2006.
Nangona kunjalo, izifundo ezininzi malunga nokusetyenziswa kweoli ye-borage ekhatyweni kwe-eczema zifumene ukuba isilungiso asiyi kuphinda sisebenze ngaphezu kwe-placebo.
2) I-Rheumatoid Arthritis
Ioli ye-Borage kunye neoli ye- primrose yamafutha ibonakalisa isithembiso ekwenzeni unyango lwe- rheumatoid arthritis , ngokubhekiselele kuphando lokuphanda olupapashwe kwi- American Journal of Clinical Nutrition ngo-2000.
Nangona ininzi yedatha kwi-oyileji ye-borage iphumelela kwi-test-tube kunye nophando lwezilwanyana, uphando oluthile oluncinane lubonisa ukuba i-borage yeoli kunye nobusuku be-oil primrose kunokunciphisa ububele kunye nokuvuvukala kubantu abane-rheumatoid arthritis.
3) Ixesha lokumisa
Nangona abaxhasi bebonisa ukuba i-gamma linolenic acid efunyenwe kwioli ye-primrose yangokuhlwa iyakunciphisa iimpawu ze-menopausal (ezifana nokutshisa okutshisa, ukusila ebusuku, ukutywa kwesisu kunye nokuphazamiseka kwemizwa), akukho ncediso lwenzululwazi yincinci. Kuphando oluphando olupapashwe kwi-American Journal of Medicine ngo-2005, umzekelo, abaphandi bahlalutya uphando lwe-19 malunga nokusetyenziswa kwezilwanyana zezilwanyana zokuphucula iimpawu ezinxulumene nokuphuma komzimba kwaye bafumanisa ukuba ioli ye-primrose yohlwaya ibonakala ingasebenzi.
4) Umhlaza
Kuphando olusenkundleni lweeseli zomhlaza, izazinzulu ziye zabonisa ukuba i-gamma linolenic acid inganciphisa ukukhula kwezidumbu kunye nokunceda ukuphucula ukuphumeza kwamachiza athile omhlaza. Nangona kunjalo, izifundo ezimbalwa ziye zavavanya iziphumo ze-gamma linolenic acid kwimhlaza kubantu.
Imijelo
Nangona i-gamma linolenic acid ngokuqhelekileyo ibonwa njengekhuselekile, kukho ukukhathazeka ukuba ukusetyenziswa kwexesha elide lokuzalisa i-gamma linolenic acid kunokunyusa umzimba kunye nokunyusa ingozi yamacenge egazi.
Ukongezelela, ioli ye-borage ingabangela ukuthambiswa , ngelixa ioli ye-primrose yangokuhlwa ingabangela isisu esisisongayo kunye nesicefe.
Izibonelelo azange zivavanywe ukhuseleko kwaye ngenxa yokuba izongezo zokutya zikhululekile kakhulu, umxholo weemveliso ezithile zingahluka kwizinto ezichaziweyo kwilebula yomkhiqizo. Kwakhona ugcine ukhumbule ukuba ukhuseleko lwezongezelelo kwabasetyhini abakhulelweyo, oomama abangabongikazi, abantwana kunye nalabo abanezifo zonyango okanye abo bathabatha imishanguzo ayilwanga. Unokufumana iingcebiso ezongezelelweyo ekusebenziseni izongezo apha .
UkuSebenzisa IzeMpilo
Kubantu abaninzi, umzimba uvelisa ngokulinganayo inani elaneleyo le-gamma-linolenic acid ngokuguqula kwi-linoleic acid (i-acid e-fatty etholakala kumanothi, imbewu, inyama kunye nemveliso yobisi).
Nangona kunjalo, abanye abantu (njengezigulane zesifo sikashukela ) abanako ukwenza okwaneleyo i-gamma-linoleic acid kwaye ngoko banokuzuza ngokuthatha i-gamma-linolenic acid kwifomu yokongeza.
Ngenxa yophando oluncitshisiweyo, kungekudala ukukhuthaza ii-GLA izongezo njengonyango kuyo nayiphi na imeko. Ukuba ucinga ukuwusebenzisa, ncokola nodokotela wakho kuqala malunga nokufaneleka kunye nemiphumo emibi. Gcina ukhumbule ukuba elinye iyeza kufuneka lingasetyenziswanga njengenxalenye yokunyamekela okuqhelekileyo. Ukuziphathela imeko kunye nokuphepha okanye ukulibazisa ukunakekelwa okuqhelekileyo kunokuba nemiphumo emibi.
> Imithombo:
> Belch JJ, Hill A. "I-Evening Primrose i-Oyile kunye neoli ye-Borage kwiimeko zeRheumatologic." Am J Clin Nutrition. 2000 71 (1 Suppl): 352S-6S.
> Henz BM, Jablonska S, PC de van Kerkhof, Stingl G, Blaszczyk M, Vandervalk PG, Veenhuizen R, Muggli R, Raederstorff D. "I-Blind-Double, i-Multicentre Ukuhlaziywa koBuchule bamafutha e-Borage kwi-Patients With Eczema." Br J Dermatol. 1999 140 (4): 685-8.
> Menendez JA. Ropero S. Lupu R. Colomer R. "I-Omega-6 i-Polyunsaturated Fatty Acty Acid i-Gamma-Linolenic Acid (18: 3n-6) Iphucula i-Docetaxel (Taxotere) I-Cytotoxicity kwi-Breast Human Breast Cells: I-Relationship ne-Lipid Peroxidation kunye ne-HER-2 / Neu . " Imibiko ye-Oncology. 2004; 11: 1241-1252.
> Morse NL, i-Clough PM. "I-Meta-Analysis ye-Randomized, i-Placebo-Controlled Trials Trials ye-Efamol Evening Primrose Oil kwi-Atticic Eczema. Curr Pharm Biotechnol. 2006 7 (6): 503-24.
> Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, Thompson JR, Chapman T, Berth-Jones J. "Ukusebenza kunye nokunyanzeliswa kweoli ye-Borage kwiBantu abadala kunye nabantwana abane-Eczema ye-Attic: I-Randomized, Blind Double, I-Placebo Elawulwayo, i-Parallel Group Trial. " BMJ. 2003 13; 327 (7428): 1385.
> Whitehouse PA, Cooper AJ, Johnson CD. Umsebenzi we-Synergistic we-Gamma-Linolenic Acid kunye ne-Cytotoxic Drugs Against Pancreatic Adenocarcinoma Cell Lines. " Pancreatology. 2003; 3: 367-373.